You are in the accessibility menu

Please use this identifier to cite or link to this item: http://acervodigital.unesp.br/handle/11449/11461
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChang, Claudia Veiga-
dc.contributor.authorFelicio, Andre Carvalho-
dc.contributor.authorNunes, Vânia dos Santos-
dc.contributor.authorCarneiro da Cunha-Neto, Malebranche Berardo-
dc.contributor.authorBarros de Castro, Ana Valeria-
dc.date.accessioned2014-05-20T13:33:26Z-
dc.date.accessioned2016-10-25T16:51:31Z-
dc.date.available2014-05-20T13:33:26Z-
dc.date.available2016-10-25T16:51:31Z-
dc.date.issued2010-01-01-
dc.identifierhttp://dx.doi.org/10.1097/TEN.0b013e3181cb47fc-
dc.identifier.citationEndocrinologist. Philadelphia: Lippincott Williams & Wilkins, v. 20, n. 1, p. 15-16, 2010.-
dc.identifier.issn1051-2144-
dc.identifier.urihttp://hdl.handle.net/11449/11461-
dc.identifier.urihttp://acervodigital.unesp.br/handle/11449/11461-
dc.description.abstractPituitary apoplexy (PA) is a rare and potentially life-threatening syndrome resulting from an acute infarction or hemorrhage of the pituitary gland. Although the pathogenesis is not fully understood, some predisposing factors such as pituitary stimulation tests, diabetes mellitus, anticoagulant or antiplatelet aggregation therapy, head trauma, and high blood pressure may play a role in its pathophysiology. Octreotide is the mainstay of medical treatment for acromegaly. The majority of reported complications of octreotide therapy are gastrointestinal. We report the case of a 51-year-old acromegalic woman who developed pituitary apoplexy within the context of high blood pressure and a single dose of long-acting octreotide. Our data suggest that the combination of hypertension and octreotide therapy enhances the risk of pituitary apoplexy.en
dc.format.extent15-16-
dc.language.isoeng-
dc.publisherLippincott Williams & Wilkins-
dc.sourceWeb of Science-
dc.subjectacromegalyen
dc.subjectpituitary apoplexyen
dc.subjectoctreotideen
dc.subjecthypertensionen
dc.titlePituitary Apoplexy After a Single Dose of Long-Acting Octreotideen
dc.typeoutro-
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)-
dc.contributor.institutionUniversidade de São Paulo (USP)-
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)-
dc.description.affiliationUniv Estadual Paulista, Dept Endocrinol, São Paulo, Brazil-
dc.description.affiliationUniv São Paulo, Neuroendocrinol Div, Neurosurg Unit, BR-09500900 São Paulo, Brazil-
dc.description.affiliationUniv Fed São Paulo, Dept Neurol, São Paulo, Brazil-
dc.description.affiliationUnespUniv Estadual Paulista, Dept Endocrinol, São Paulo, Brazil-
dc.identifier.doi10.1097/TEN.0b013e3181cb47fc-
dc.identifier.wosWOS:000274057900006-
dc.rights.accessRightsAcesso restrito-
dc.relation.ispartofEndocrinologist-
Appears in Collections:Artigos, TCCs, Teses e Dissertações da Unesp

There are no files associated with this item.
 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.